# Program 1: Cancer Genes and Pathways

> **NIH NIH P30** · UNIVERSITY OF IOWA · 2020 · $299,112

## Abstract

Research in the newly restructured Cancer Genes and Pathways (CGP) program focuses on the study of
biologically significant genetic alterations and molecular pathways that underlie cancer development and
immune surveillance. The primary goal of this basic science program is to better understand fundamental
mechanisms of tumorigenesis and cancer immunology, thereby defining new molecular entities that can be
exploited as disease biomarkers and/or innovative anti-cancer therapies. This is accomplished through three
overlapping research themes centered on 1) genome organization, regulation and cancer gene expression, 2)
cellular proliferation, survival and transformation, and 3) tumor immunosurveillance. Key scientific
achievements over the prior funding period include advances in understanding mechanisms of damaged DNA
repair and replication, identification and characterization of novel tumor-promoting genetic alterations and
cancer gene networks, development of innovative animal models of cancer, and determination of pathways
controlling B and T lymphocyte survival and activation. CGP membership includes 54 full and 6 associate
members spanning 16 departments (10 basic science, 6 clinical) across 3 colleges. Annual CGP total funding
for peer-reviewed research in the last budget year was $10.36 million ($2.00 NCI funding) and $1.99 million for
non-peer-reviewed research projects. CGP members are highly collaborative having authored or co-authored
353 cancer-related peer-reviewed publications in the past 4 years, with 17% (n=59) intra-programmatic, 22%
(n=77) inter-programmatic, and 32% (n=113) inter-institutional. 49 manuscripts appeared in high impact
journals (Impact Factor >10). Productive intra-/inter-programmatic and multi-institutional groups are leading
advances in mature B lineage tumors (myeloma and non-Hodgkin's lymphomas) and neuroendocrine tumor
research, and making major contributions to other human malignancies including leukemias, breast cancer,
prostate cancer, melanoma, pancreatic adenocarcinoma and liver cancers.

## Key facts

- **NIH application ID:** 10243423
- **Project number:** 3P30CA086862-20S6
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** DAWN E QUELLE
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $299,112
- **Award type:** 3
- **Project period:** 2000-07-14 → 2021-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10243423

## Citation

> US National Institutes of Health, RePORTER application 10243423, Program 1: Cancer Genes and Pathways (3P30CA086862-20S6). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10243423. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*